WALLFLEX BILIARY TRANSHEPATIC UNCOVERED STENT SYSTEM, WALLFLEX BILIARY TRANSHEPATIC COVERED STENT SYSTEM
Device Facts
| Record ID | K112543 |
|---|---|
| Device Name | WALLFLEX BILIARY TRANSHEPATIC UNCOVERED STENT SYSTEM, WALLFLEX BILIARY TRANSHEPATIC COVERED STENT SYSTEM |
| Applicant | Boston Scientific Corporation |
| Product Code | FGE · Gastroenterology, Urology |
| Decision Date | Dec 29, 2011 |
| Decision | SESU |
| Submission Type | Traditional |
| Regulation | 21 CFR 876.5010 |
| Device Class | Class 2 |
| Attributes | Therapeutic |
Indications for Use
The WallFlex Biliary Transhepatic Stent System is indicated for use in the palliative treatment of biliary strictures produced by malignant neoplasms.
Device Story
WallFlex Biliary Transhepatic Stent System consists of an implantable stent and a delivery system. Stents are available in uncovered, fully covered, or partially covered configurations (Permalume covering). Stent wires feature a radiopaque core for imaging. Delivery system includes radiopaque marker bands to assist in deployment and accommodates a 0.035-inch guidewire. Used by clinicians for transhepatic placement to maintain patency in malignant biliary strictures. Device provides mechanical support to the biliary duct, facilitating bile flow and palliating symptoms. Safety and effectiveness for vascular use have not been established.
Clinical Evidence
Bench testing only. No clinical data provided. Biocompatibility testing (Cytotoxicity, Sensitization, Irritation, Acute Systemic Toxicity, USP Physicochemical, Material Mediated Rabbit Pyrogen) performed on delivery system components. Performance testing confirmed substantial equivalence regarding deployment, reconstrainment, guidewire passage, and trackability/pushability.
Technological Characteristics
Stent system with radiopaque-core wires; available uncovered or with Permalume covering. Delivery system includes radiopaque marker bands; 0.035-inch guidewire compatibility. Biocompatibility evaluated per EN ISO 10993-1:2009. Mechanical design and materials identical to predicate WallFlex and Wallstent systems.
Indications for Use
Indicated for palliative treatment of biliary strictures caused by malignant neoplasms in patients requiring biliary stenting.
Regulatory Classification
Identification
A biliary catheter and accessories is a tubular flexible device used for temporary or prolonged drainage of the biliary tract, for splinting of the bile duct during healing, or for preventing stricture of the bile duct. This generic type of device may include a bile collecting bag that is attached to the biliary catheter by a connector and fastened to the patient with a strap.
Special Controls
*Classification.* Class II (special controls). The device, when it is a bile collecting bag or a surgical biliary catheter that does not include a balloon component, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 876.9.
Predicate Devices
- Wallstent Transhepatic Biliary Endoprosthesis (K964119)
- Wallstent Biliary Endoprosthesis (K000308)
- Wallstent Biliary Endoprosthesis (K993232)
- WallFlex Biliary RX Stent System (K061231)
- WallFlex Biliary RX Stent System (K081733)
- WallFlex Biliary RX Stent System (K083374)
- WallFlex Biliary RX Stent System (K083627)
Submission Summary (Full Text)
{0}------------------------------------------------
K112543
page 1 of 2
DEC 2 9 2011
SECTION 5 510(k) SUMMARY
### 1. Submitter
Boston Scientific Corporation 100 Boston Scientific Way Marlborough, MA 01752 Telephone: 508-683-4454 Fax: 508-683-5939
Contact: Thomas Hirte Senior Manager Regulatory Affairs Date Prepared: August 04, 2011
#### 2. Device
Trade Name: WallFlex™ Biliary Transhepatic Stent System Biliary Stent system Common Name: Biliary catheter and accessories Classification Name: 876.5010 Regulation Number: FGE Product Code: Classification: Class II
# 3. Predicate Devices
The Boston Scientific Corporation, Wallstent Transhepatic Biliary Endoprosthesis (K964119), the Boston Scientific Corporation, Wallstent Biliary Endoprosthesis (K000308, K993232) , and the Boston Scientific Corporation, WallFlex Biliary RX Stent System (K061231, K081733, K083374, and K083627).
#### 4. Device Description
The WallFlex™ Biliary Transhepatic Stent System is comprised of two components: the implantable WallFlex Biliary Transhepatic stent and the delivery system.
The stent is offered uncovered or covered. The covered stents are offered as fully covered, or partially covered with a Permalume™ stent covering. The stent wires have a radiopaque core to improve radiopacity.
The stent is preloaded onto the delivery system, which has radiopaque marker bands used to aid in imaging during deployment of the stent. The delivery system accommodates a 0.035 in (0.89 mm) guidewire.
#### 5. Indication for Use:
The WallFlex Biliary Transhepatic Stent System is indicated for use in the palliative treatment of biliary strictures produced by malignant neoplasms.
{1}------------------------------------------------
K112543
page 2 of 2
# 6. Technological Characteristics:
The proposed WallFlex Transhepatic Biliary Stent System has the same technological characteristics (such as the stent and delivery system dimensions, materials, and design features) as the predicate Wallstent Transhepatic Biliary Stent System (K964119), the Wallstent Biliary Endoprosthesis (K000308, K993232), and the WallFlex Biliary RX Stent System (K061231, K081733, K083374, and K083627).
The proposed device has the same intended use and is placed using the same methodology as the predicate device (Wallstent Transhepatic Biliary Stent System) via a flexible delivery system.
# 7. Performance Data:
Biocompatibility and performance testing was performed on the proposed WallFlex Biliary Transhepatic Stent System.
#### Biocompatibility Testing Summary:
The proposed stent is identical to the current WallFlex Biliary RX Stent (K061231, K081733, K083374, and K083627), and therefore no further biocompatibility testing was done on the stent. The proposed delivery system is manufactured utilizing identical materials that are used on the current predicate devices. Biocompatibility was evaluated in accordance with EN ISO 10993-1:2009, and the following tests were performed on the delivery system: Cytotoxicity, Sensitization, Irritation, Acute Systemic Toxicity, USP Physicochemical Test, and Material Mediated Rabbit Pyrogen Test.
# Performance Testing Summary:
Comparative performance testing was successfully completed to establish substantial equivalence between the proposed WallFlex Biliary Transhepatic Stent System and the predicate devices. This testing included but was not limited to deployment, reconstrainment, guidewire passage, and trackability/pushability.
#### 8. Conclusion:
All biocompatibility tests conducted on the WallFlex Biliary Transhepatic Stent System passed. Therefore, the WallFlex Biliary Transhepatic Stent System is considered biocompatible for its intended use.
All device bench test results were acceptable. The data demonstrate that the WallFlex Biliary Transhepatic Stent System sufficiently meets the design specifications and is suitable for the intended use.
Boston Scientific has demonstrated that the proposed WallFlex Biliary Transhepatic Stent System is substantially equivalent to Boston Scientific Corporations currently marketed Wallstent Biliary Transhepatic Stent System (K964119), the Wallstent Biliary Endoprosthesis (K000308, K993232), and the Boston Scientific WallFlex Biliary RX Stent System (K061231, K081733, K083374, and K083627).
{2}------------------------------------------------
Image /page/2/Picture/1 description: The image is a circular seal for the Department of Health & Human Services USA. The seal features a stylized eagle with its wings spread, facing right. The words "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" are arranged in a circular pattern around the eagle.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Room -WO66-G609 Silver Spring, MD 20993-0002
Mr. Thomas Hirte Senior Manager, Regulatory Affairs Boston Scientific Corporation 100 Boston Scientific Way MARLBOROUGH MA 01752
DEC 2 9 2011
Re: K112543
Trade/Device Name: WallFlex® Biliary Transhepatic Stent System Regulation Number: 21 CFR §876.5010 Regulation Name: Biliary catheter and accessories Regulatory Class: II Product Code: FGE Dated: December 21, 2011 Received: December 22, 2011
Dear Mr. Hirte:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act and the limitations described below. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
The Office of Device Evaluation has determined that there is a reasonable likelihood that this device will be used for an intended use not identified in the proposed labeling and that such use could cause harm. Therefore, in accordance with Section 513(i)(1)(E) of the Act, the following limitation must appear in the Warnings section of the device's labeling:
The safety and effectiveness of this device for use in the vascular system have not been established.
Furthermore, the indication for biliary use must be prominently displayed in all labeling, including pouch, box, and carton labels, instructions for use, and other promotional materials, in close proximity to the trade name, of a similar point size, and in bold print.
Please note that the above labeling limitations are required by Section 513(i)(1)(E) of the Act. Therefore, a new 510(k) is required before these limitations are modified in any way or removed from the device's labeling.
{3}------------------------------------------------
# Page 2 - Mr. Thomas Hirte
The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and permits your device to proceed to the market. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification if the limitation statement described above is added to your labeling.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.goy/MedicalDevices/Resourcesfor You/Industry/default.htm.
Sincerely yours,
Mark Mikkelsen
f
Christy Foreman Director Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{4}------------------------------------------------
# Indications for Use
510(k) Number (if known): K112543
Device Name: WallFlex® Biliary Transhepatic Stent System
Indications For Use: The WallFlex Biliary Transhepatic Stent System is indicated for use in the palliative treatment of biliary strictures produced by malignant neoplasms.
Prescription Use
(Part 21 CFR 801 Subpart D)
AND/OR
Over-The-Counter Use (21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
ductive, Gastro-Renal, and 10(k) Numbe
Page 1 of ____________________________________________________________________________________________________________________________________________________________________
